Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash from Financing Activities (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Cash from Financing Activities for 14 consecutive years, with $147823.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 129.02% year-over-year to $147823.0, compared with a TTM value of $8.7 million through Dec 2025, up 56.37%, and an annual FY2025 reading of $8.0 million, up 10.45% over the prior year.
  • Cash from Financing Activities was $147823.0 for Q4 2025 at Neuroone Medical Technologies, up from $66978.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $12.0 million in Q4 2021 and bottomed at -$509325.0 in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $2.3 million, with a median of $933487.5 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities surged 205677.95% in 2023, then plummeted 142.27% in 2024.
  • Year by year, Cash from Financing Activities stood at $12.0 million in 2021, then crashed by 100.13% to -$15713.0 in 2022, then soared by 7768.9% to $1.2 million in 2023, then plummeted by 142.27% to -$509325.0 in 2024, then skyrocketed by 129.02% to $147823.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for NMTC at $147823.0 in Q4 2025, $66978.0 in Q3 2025, and $8.2 million in Q2 2025.